Daily Pill Can Double Survival Time for World’s Deadliest Cancer, Trial Shows A clinical trial involving 500 advanced pancreatic cancer patients demonstrated that the daily pill daraxonrasib doubled survival time, with patients living an average of 13.2 months compared to 6.6-6.7 months with chemotherapy. The drug targets the Kras protein, which fuels nearly all pancreatic cancers, offering a new approach with fewer side-effects. Experts are hailing the results as a major breakthrough and a potential ‘gamechanger’ in pancreatic cancer treatment, with hopes for similar advancements in other cancers.

• A daily pill called daraxonrasib has doubled survival time in patients with advanced pancreatic cancer, according to a clinical trial.
• The drug targets the Kras protein, a key driver in nearly all pancreatic cancers, by gluing molecules to shut it down.
• In a trial of 500 patients, those taking daraxonrasib lived an average of 13.2 months, compared to 6.6-6.7 months for those on chemotherapy.
• Experts are calling the results a ‘gamechanger’ and a significant breakthrough, with potential implications for other cancer types fueled by Ras genes.
• The discovery offers new hope for patients with pancreatic cancer, a disease with historically limited treatment options and low survival rates.